CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 302 enrolled
Drug / intervention
Blazer® Open-Irrigated Ablation Catheter +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01253200
NCT01253200N/ACompleted
CompareCT.gov

Clinical Evaluation of the Blazer® Open-Irrigated Radiofrequency Ablation Catheter for the Treatment of Type 1 Atrial Flutter

Boston Scientific Corporation·interventional·Posted Dec 3, 2010·Updated Mar 19, 2018

In Brief

A clinical study evaluating Blazer® Open-Irrigated Ablation Catheter and Control Catheter for Atrial Flutter. Completed, enrolled 302 participants across 26 sites.

Detailed Summary

The purpose of the BLOCk-CTI study is to evaluate the safety and effectiveness of the Blazer® Open-Irrigated Ablation Catheter for the treatment of sustained or recurrent type 1 atrial flutter. This study will compare outcomes in patients treated with the Blazer® Open-Irrigated Ablation Catheter to outcomes in patients treated with open-irrigated radiofrequency ablation catheters that have received FDA market approval for the treatment of type 1 atrial flutter.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Flutter
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 3, 2010
Enrollment StartJan 1, 2011
Primary CompletionSep 1, 2013
Study CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 15.6 years ago

Interventions

Blazer® Open-Irrigated Ablation Catheterdevice

Blazer® Open-Irrigated Ablation Catheter

Control Catheterdevice

Open-irrigated radiofrequency ablation catheters that have received FDA market approval for the treatment of type 1 atrial flutter